Peptide record

TPDB25929

Antibacterial Anticancer Toxicity standard
20 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB25929
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia
standard
No
A 20-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Sequence
TLYKKFRHFLKKPWHVVGKI
Physicochemical Analysis
C125H193N33O23
ANDCEQMS
K
2526.12
11.14
8
0
9
+6
1.94
-0.460
87.50
Mammalian: 7.2 hour Yeast: >20 hour E.coli: >10 hour
6990
276.71
2
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
0
E
0
Q
1
G
2
H
1
I
2
L
5
K
0
M
2
F
1
P
0
S
1
T
1
W
1
Y
2
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 2 I: 1 L: 2 K: 5 M: 0 F: 2 P: 1 S: 0 T: 1 W: 1 Y: 1 V: 2
Chemical Descriptors
20
C125H193N33O23
2526.12
11.14
+6
1.94
-0.460
Evidence Records 3 records
Evidence 1 Activity

Activity

EC50
Toxicity
167±13 µM
Cytotoxic
EC50 | 167±13 | µM | target cell: Human dermal microvascular endothelial cells HDME

Target

Human dermal microvascular endothelial cells HDME

Source & Reference

NA
DBAASP
In silico design and optimization of selective membranolytic anticancer peptides. | Sci Rep | 2019
Evidence 2 Activity

Activity

50% Hemolysis
Toxicity
>200 µM
Hemolytic Cytotoxic
50% Hemolysis | >200 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
In silico design and optimization of selective membranolytic anticancer peptides. | Sci Rep | 2019
Evidence 3 Activity

Activity

HC50
Toxicity
200 µM
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: HC50>200 µM | Cytotoxicity: HDMEC: EC50=167 ± 13 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Sci Rep. 2019 Aug 2 9(1):11282.